Financial Architects, Inc Neurocrine Biosciences Inc Transaction History

Financial Architects, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 06, 2019	SELL	$83.82 - $101.5 $1,424 - $1,725	-17 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $69,928 - $88,349	-968 Reduced 98.27%	17 $1,000
Q1 2019 May 13, 2019	SELL	$69.31 - $91.53 $8,109 - $10,709	-117 Reduced 10.62%	985 $86,000
Q4 2018 Feb 01, 2019	SELL	$68.32 - $124.36 $19,334 - $35,193	-283 Reduced 20.43%	1,102 $78,000
Q3 2018 Oct 29, 2018	BUY	$98.88 - $125.85 $101,253 - $128,870	1,024 Added 283.66%	1,385 $170,000
Q2 2018 Aug 03, 2018	BUY	$75.3 - $105.99 $27,183 - $38,262	361 New	361 $35,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.